Mogroside IIIE, a Novel Anti-Fibrotic Compound, Reduces Pulmonary Fibrosis through Toll-Like Receptor 4 Pathways

(L.T., J.Y., F.C., M.Z., C.Z.,) Research Department of Pharmacognosy, China Pharmaceutical University, Nanjing, People’s Republic of China; (Y.G.) Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; and (H.X.) Chengdu Biopurity Phytochemicals Ltd. Chengdu, People’s Republic of China

Address correspondence to:
Dr. Yanqing Gong, Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Smilow Center for Translational Research, Room 11-142, Philadelphia, PA, 19104. E-mail: gongy{at}mail.med.upenn.edu or Dr. Chaofeng Zhang, Research Department of Pharmacognosy, China Pharmaceutical University, 639 Longmian Road, Nanjing 210098 P.R. China. E-mail: zhangchaofeng{at}cpu.edu.cn